Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AndroMETa-GEA-977: Telisotuzumab adizutecan + fluorouracil/leucovorin + budigalimab in first-line advanced gastric/GEJ/esophageal adenocarcinoma
2024-513008-32-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Mar 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised trial of telisotuzumab adizutecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC), sponsored by AbbVie Inc. Primary endpoints: Progression-free survival (PFS) and Objective response (CR or PR). Planned start Mar 2025; status: authorised.
02
Drugs
telisotuzumab adizutecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2024-513008-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513008-32-00.